Core Laboratories NV (CLB) Research Coverage Started at Loop Capital
Other analysts have also recently issued reports about the company. Citigroup Inc. decreased their price objective on Core Laboratories NV from $123.00 to $118.00 and set a neutral rating on the stock in a report on Monday, July 25th. KLR Group restated a buy rating and set a $180.00 price target (up previously from $166.00) on shares of Core Laboratories NV in a report on Monday, June 13th. JPMorgan Chase & Co. lowered Core Laboratories NV from a neutral rating to an underweight rating in a report on Tuesday, July 12th. Credit Suisse Group AG started coverage on Core Laboratories NV in a report on Thursday, September 1st. They set a neutral rating and a $115.00 price target on the stock. Finally, Zacks Investment Research lowered Core Laboratories NV from a strong-buy rating to a hold rating in a report on Tuesday, July 26th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $120.47.
Shares of Core Laboratories NV (NYSE:CLB) opened at 111.87 on Friday. The company has a market cap of $4.93 billion, a PE ratio of 59.35 and a beta of 1.45. The company has a 50-day moving average of $111.48 and a 200 day moving average of $117.54. Core Laboratories NV has a 12-month low of $84.50 and a 12-month high of $135.49.
Core Laboratories NV (NYSE:CLB) last issued its quarterly earnings data on Wednesday, July 20th. The company reported $0.35 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.35. The business had revenue of $148.10 million for the quarter, compared to analysts’ expectations of $146.37 million. Core Laboratories NV had a return on equity of 344.55% and a net margin of 11.81%. The company’s revenue for the quarter was down 27.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.81 EPS. On average, equities research analysts expect that Core Laboratories NV will post $1.55 EPS for the current year.
A number of large investors have recently modified their holdings of CLB. Emerald Acquisition Ltd. bought a new stake in shares of Core Laboratories NV during the second quarter worth $110,515,000. Royal Bank of Canada increased its stake in shares of Core Laboratories NV by 416.8% in the second quarter. Royal Bank of Canada now owns 475,077 shares of the company’s stock worth $58,857,000 after buying an additional 383,153 shares during the last quarter. Norges Bank bought a new stake in shares of Core Laboratories NV during the fourth quarter worth $38,759,000. Bessemer Group Inc. increased its stake in shares of Core Laboratories NV by 40.0% in the first quarter. Bessemer Group Inc. now owns 1,102,126 shares of the company’s stock worth $123,890,000 after buying an additional 315,123 shares during the last quarter. Finally, Fiera Capital Corp bought a new stake in shares of Core Laboratories NV during the second quarter worth $26,853,000.
About Core Laboratories NV
Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.
Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.